1. Short title This Act may be cited as the Preserving Patient Access to Compounded Medications Act of 2017 . 2. Office-use compounding when authorized by State law Section 503A(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 353a(a) ) is amended— (1) in the matter preceding paragraph (1), by inserting or drug order for administration to a patient in an office or clinical setting after is necessary for the identified patient ; (2) in paragraph (1), by striking or at the end; (3) in paragraph (2), by striking the period at the end and inserting ; or ; and (4) by adding at the end the following new paragraph: (3) is by a licensed pharmacist or licensed physician pursuant to a valid prescription order or drug order and the compounded drug is distributed or dispensed to a licensed prescriber in accordance with State law, for administration to a patient in an office or clinical setting. . 3. United States pharmacopoeia or national formulary monograph requirement Section 503A(b)(1)(A) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 353A(b)(1)(A) ) is amended— (1) in the matter preceding subclause (i), by inserting , or dietary supplements after Regulations ; and (2) in clause (i)— (A) by amending subclause (I) to read as follows: (I) comply with the monograph standards in any section of the of the United States Pharmacopoeia or National Formulary, including drug substance or dietary supplement monograph, if a monograph exists. ; and (B) by amending subclause (III) to read as follows: (III) if such monograph does not exist and the drug substance or dietary supplement is not a component of a drug approved by the Secretary, but appears on a list developed by the Secretary through regulations issued by the Secretary under subsection (c) of this section